We would love to hear your thoughts about our site and services, please take our survey here.
Personally don’t think we will be announced as the sovereign test this week. Looking at omegas tweets, they seem to be under the impression it will be announced after the local elections so I’m thinking CE mark this week and government contract next week
*facepalm"- scinv, you're digging yourself a hole here. Please stop trying to act smart about things you honestly don't have the faintest idea about. I am not going down a tit for tat alley with this one, thats the last I will say on this. For those that understand how it works, understands what I am talking about.
and please bare in mind that a lot of what is in the abpi is also bound by UK law. I do not know of a single UK pharma company that is either not a member nor has formally accepted the code. Anyway, going down a tangent now.
Look at the numbers the testing companies are getting for their antigen and antibody tests, taking them similar times to recruit very few patients. Its an issue all round.
Atea have an antiviral they are developing with Roche. PII was expected a while back, but radio silence.
Recruitment is providing to be far more difficult than people anticipated across the board.
andyrp- granted SNG is not a member, but you have shown that you have a very limited knowledge of pharma with that comment. Being an ABPI member is what every single pharma company aspires do in this country. Whether you are a member or not, acting in such accord is something all pharma companies in the UK strive to do and rightfully so. This isn't America.
Docdaneeka- you hit the nail on the head with both your posts there and especially "our initial reponse was overwhelmingly positive and that was the correct response". Sub par presenting skills seems to have spooked most people here. Add on the dips and just be patient over the next 4-6 months
Maybe you are referring to Advanced Budgetary Notifications? Again, not something which they can discuss in a presentation setting, only with appropriate people in the NHS who are buyers.
Nonetheless, we are on the same page here.
fair enough nitro.
The deramping comments do amuse me from others however. They seem to have bought in on the 200p highs are now venting their frustrations. Again, similar to those that bought at 75p and saw the SP dip to 40p. Fact is, covid isn't going, probably not in our lifetime, it will always need treating and especially over the next 2-3 years. The phase 2 had no issues at all, no uncertainties, the phase 3 has just been de-risked by todays information with us now knowing that the population chosen is THE best population for the drug to work.
But it seems like most people on aim only care about presentation delivery...
It is obvious to me that the majority of people here haven't worked in pharma and don't know what the ABPI code of practice is. When a company releases a press statement or conference about an UNLICENSED medication, it is purely NON-PROMOTIONAL. They cannot raise unfounded hope, promote the drug in ANY WAY or induce prescribing in ANY WAY. They cannot promote to the public, make any claims they cannot substantiate with data (there was no statistical significance in this trial) and would risk several clause breaches and fines.
Therefore, you CANNOT expect them to have a jovial, uber promotional presentation about an unlicensed drug, especially after a trial which showed no statistical or clinical significance.
In regards to the data, I personally feel the drop is undue, the results are in line with what is to be expected in the setting, coupled with the fact a lot of patients had mild disease I think it is acceptable. This trial has done one main thing and that is highlight which setting the drug should be used in and has reaffirmed the companies trial design and inclusion critera for PIII. I have absolutely ZERO doubt in my mind that PIII will be super positive. I will be adding on all dips and this has now become a conviction play for me. I expect PIII Sept-Nov.